https://ebdgroup.knect365.com/biotech...
In an interview at Biotech Showcase in San Francisco, Josep Bassaganya-Riera, CEO of Landos Biopharma, shares his startup's vision for developing oral drugs for autoimmune diseases, including the lead compound BT-11 for Crohn's disease. The Blacksburg, Virginia-based company was founded in 2017 as a spin-off of Biotherapeutics, which specializes in advanced computational modeling for development of personalized therapeutics. The technology is agnostic and may be applied to a range of disease areas; Landos was established with a focus on applying the IT infrastructure in autoimmune disease. Bassaganya-Riera believes that the drugs his company is developing will one day offer an attractive alternative to the biologics widely used today in autoimmune diseases, but which work in only 30% to 40% of patients.